Literature DB >> 17890459

Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study.

Angelo M Taveira-DaSilva1, Olanda M Hathaway, Vandana Sachdev, Yukitaka Shizukuda, Charles W Birdsall, Joel Moss.   

Abstract

BACKGROUND: Exercise-induced hypoxemia is frequent in patients with lymphangioleiomyomatosis (LAM) and could be associated with pulmonary hypertension. The aims of this study were to determine the prevalence of pulmonary hypertension in patients with LAM, to identify physiologic parameters associated with its occurrence, and to evaluate the effect of oxygen on response to exercise.
METHODS: Studies were performed in 120 patients. Complete data, including exercise echocardiography, pulmonary function testing, and standard cardiopulmonary exercise testing, were obtained in 95 patients.
RESULTS: Resting pulmonary artery pressure (PAP) was 26+/-0.7 mm Hg (mean+/-SEM). Eight patients had pulmonary hypertension (43+/-3 mm Hg), and two patients had right ventricular dilatation. Ninety-five patients exercised (room air, n=64; oxygen, n=31) to a power of 58+/-2 W (49% of predicted) and an estimated peak oxygen uptake of 938+/-30 mL/min (56% of predicted). Sixty-one patients had a decline in arterial oxygen saturation (SaO2)>3%, and 56 patients had an elevation in PAP>40 mm Hg. Peak exercise PAP was negatively correlated with exercise Sao2 (p=0.0005). Multivariate analysis showed that exercise SaO2 was the best predictor of exercise PAP (p=0.012).
CONCLUSIONS: Although resting pulmonary hypertension is rare in patients with LAM, a rise in PAP at low exercise levels occurs frequently, in part related to exercise-induced hypoxemia. Optimization of oxygen administration during activities of daily living should be undertaken in patients with LAM to prevent hypoxemia and exercise-induced pulmonary hypertension.

Entities:  

Mesh:

Year:  2007        PMID: 17890459      PMCID: PMC2946895          DOI: 10.1378/chest.07-1205

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  36 in total

1.  Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease.

Authors:  Selim M Arcasoy; Jason D Christie; Victor A Ferrari; Martin St John Sutton; David A Zisman; Nancy P Blumenthal; Alberto Pochettino; Robert M Kotloff
Journal:  Am J Respir Crit Care Med       Date:  2002-12-12       Impact factor: 21.405

2.  Stress Doppler echocardiography for identification of susceptibility to high altitude pulmonary edema.

Authors:  E Grünig; D Mereles; W Hildebrandt; E R Swenson; W Kübler; H Kuecherer; P Bärtsch
Journal:  J Am Coll Cardiol       Date:  2000-03-15       Impact factor: 24.094

3.  Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score.

Authors:  K Matsui; M B Beasley; W K Nelson; P M Barnes; J Bechtle; R Falk; V J Ferrans; J Moss; W D Travis
Journal:  Am J Surg Pathol       Date:  2001-04       Impact factor: 6.394

4.  Pulmonary artery systolic pressures estimated by echocardiogram vs cardiac catheterization in patients awaiting lung transplantation.

Authors:  A Homma; A Anzueto; J I Peters; I Susanto; E Sako; M Zabalgoitia; C L Bryan; S M Levine
Journal:  J Heart Lung Transplant       Date:  2001-08       Impact factor: 10.247

5.  Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis.

Authors:  A M Taveira-DaSilva; C Hedin; M P Stylianou; W D Travis; K Matsui; V J Ferrans; J Moss
Journal:  Am J Respir Crit Care Med       Date:  2001-09-15       Impact factor: 21.405

6.  Pulmonary hypertension in patients with idiopathic pulmonary fibrosis.

Authors:  Hassan F Nadrous; Patricia A Pellikka; Michael J Krowka; Karen L Swanson; Nithima Chaowalit; Paul A Decker; Jay H Ryu
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

7.  Benefits of oxygen on exercise performance and pulmonary hemodynamics in patients with COPD with mild hypoxemia.

Authors:  Keisaku Fujimoto; Yukinori Matsuzawa; Shinji Yamaguchi; Tomonobu Koizumi; Keishi Kubo
Journal:  Chest       Date:  2002-08       Impact factor: 9.410

Review 8.  Pulmonary hypertension in chronic obstructive pulmonary disease.

Authors:  J A Barberà; V I Peinado; S Santos
Journal:  Eur Respir J       Date:  2003-05       Impact factor: 16.671

9.  Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures.

Authors:  Magdalena Karbowniczek; Jane Yu; Elizabeth Petri Henske
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

10.  Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial.

Authors:  Hossein Ardeschir Ghofrani; Ralph Wiedemann; Frank Rose; Ralph T Schermuly; Horst Olschewski; Norbert Weissmann; Andreas Gunther; Dieter Walmrath; Werner Seeger; Friedrich Grimminger
Journal:  Lancet       Date:  2002-09-21       Impact factor: 79.321

View more
  18 in total

1.  [Histopathological aspects of pulmonary hypertension].

Authors:  D Jonigk; M M Hoeper; H Kreipe; F Länger
Journal:  Pathologe       Date:  2012-05       Impact factor: 1.011

2.  Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.

Authors:  Arnold S Kristof; Zhipeng You; Yin-Shan Han; Adel Giaid
Journal:  Peptides       Date:  2010-04-28       Impact factor: 3.750

3.  A National Heart, Lung, and Blood Institute history and perspective on lymphangioleiomyomatosis.

Authors:  Hannah Peavy; Dorothy Gail; James Kiley; Susan Shurin
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

4.  Characterization of lymphangioleiomyomatosis patients with discordance between spirometric and diffusion measurements of pulmonary function.

Authors:  Andrew M Courtwright; Bruno G Baldi; Pranav Kidambi; Ye Cui; Anthony M Lamattina; Julian A Villalba; Shefali Bagwe; Hilary J Goldberg; Ivan O Rosas; Elizabeth Petri Henske; Carlos R R Carvalho; Souheil El-Chemaly
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

5.  Involvement of lymphatics in lymphangioleiomyomatosis.

Authors:  Connie G Glasgow; Angelo Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Katsuya Tsukada; Xiong Cai; Souheil El-Chemaly; Joel Moss
Journal:  Lymphat Res Biol       Date:  2009-12       Impact factor: 2.589

6.  The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis.

Authors:  Angelo M Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Joel Moss
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

Review 7.  Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?

Authors:  Jason Weatherald; Laurent Savale; Marc Humbert
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

Review 8.  Pulmonary Hypertension and Cancer: Etiology, Diagnosis, and Management.

Authors:  Fatima A Ballout; Ahmad S Manshad; Tochukwu M Okwuosa
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-06

9.  Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene.

Authors:  Wendy K Steagall; Gustavo Pacheco-Rodriguez; Connie G Glasgow; Yoshihiko Ikeda; Jing-Ping Lin; Gang Zheng; Joel Moss
Journal:  Am J Pathol       Date:  2013-07-16       Impact factor: 4.307

10.  Risk factors for right ventricular dysfunction in patients with lymphangioleiomyomatosis.

Authors:  Wei Hua; Wenbo Yang; Jianing Gu; Jialiang Wu; Wei Wang; Yanpu Liu; Hong Zhu; Min Zhou; Jieming Qu; Yuehua Fang
Journal:  Int J Cardiovasc Imaging       Date:  2020-09-14       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.